The ALS Association is committing $3.5 million, including a $1 million commitment from its Greater New York chapter, while the Tow Foundation is contributing $2.5 million.
New Scientist reports that researchers have tested an ALS gene therapy in a mouse model of disease.
The assay was shown to have a simpler workflow and was able to detect mosaicism, with only a slight decrease in sensitivity compared to a lab-developed test.
The New York Genome Center created MetroNome as a way to show genomic data in the context of phenotypes, but integration challenges lie ahead.
Silicon Valley VC firm DFJ led the investment in Verge, which is applying machine learning to the development of new drugs for Parkinson's and ALS.
Using large-scale GWAS data, researchers saw shared genetic contributors for ALS and frontotemporal dementia, as well as ALS and progressive supranuclear palsy.
Amarantus has reacquired LymPro Test, MSPrecise, and NuroPro and said that it plans to assign the assets to a new subsidiary.
Both a genome-wide association study and a rare variant burden analysis homed in on a role for KIF5A mutations in amyotrophic lateral sclerosis.
Gizmodo wonders whether CRISPR could present a treatment for amyotrophic lateral sclerosis.
In Science this week: genomic studies of how fungal pathogen overcomes resistant wheat plants, and more.
The New York Times Magazine examines gender discrimination at the Salk Institute.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.